BMJ:托珠单抗治疗对重症及危重新冠肺炎患者临床改善作用不明显

2021-01-23 MedSci原创 MedSci原创

在重症或危重covid-19患者中,在标准治疗方案基础上添加托珠单抗不能改善患者15天临床结果,并且可能与死亡率增加有关

截至2020年10月,全球新冠肺炎患者已超过4000万,其中超过100万患者死亡。虽然大多数新冠肺炎患者是无症状的或轻症患者,但仍有部分患者病情严重,可发展为低氧血症、呼吸衰竭、休克、器官功能障碍,最终导致死亡。新冠肺炎感染后,肺部会出现因感染导致的巨噬细胞激活,随着病情加重,会发展为全身系统性激活,因此宿主免疫反应被认为在covid-19肺和其他器官功能障碍的病理过程中起着关键作用。托珠单抗是一种白细胞介素6抑制剂,用于治疗类风湿关节炎、巨细胞动脉炎和CAR-T细胞因子释放综合征。近日研究人员考察了其对重症及危重症covid-19患者预后的影响。
 
本次研究为随机,开放标签试验,在巴西9家医院开展。covid-19成年患者参与,患者接受吸氧或机械通气,并且至少有两个血清生物标志物(C反应蛋白、D二聚体、乳酸脱氢酶或铁蛋白)的水平异常,在标准护理基础上,接受单次静脉滴注8 mg/kg托珠单抗(n=65)或安慰剂(n=64)。研究的主要终点为15天时临床状态,以7级序贯量表评估。
 
129名患者,平均年龄57岁,68%为男性,所有患者均完成了随访。托珠单抗组所有患者和标准护理组的两名患者均接受了托珠单抗治疗。托珠单抗组65名患者中有18例(28%)接受机械通气或在15天内死亡,而标准护理组64例患者中有13例(20%,比值比1.54)。托珠单抗组11例(17%)患者在15天内死亡,而标准治疗组的2例(3%,风险比6.42)。在67例接受托珠单抗治疗的患者中,有29例(43%)出现不良事件,62例安慰剂组患者中,有21例(34%)出现不良事件。
 
研究发现,在重症或危重covid-19患者中,在标准治疗方案基础上添加托珠单抗不能改善患者15天临床结果,并且可能与死亡率增加有关。
 
原始出处:
 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1212082, encodeId=53251212082d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Apr 18 08:09:07 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849168, encodeId=6f1118491685d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Aug 13 11:15:23 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919315, encodeId=925691931572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210123/de3e3cb777b342e0a1c1276de5bf1b9a/9325fbaec7b940728d61b380ff227dde.jpg, createdBy=46a42697416, createdName=ent_xunmeng1987, createdTime=Sat Jan 23 23:15:25 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029022, encodeId=cde4102902231, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Jan 23 14:15:23 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919205, encodeId=d6839192052e, content=<a href='/topic/show?id=e0d7546812c' target=_blank style='color:#2F92EE;'>#托珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=428, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54681, encryptionId=e0d7546812c, topicName=托珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 23 13:55:49 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919188, encodeId=382091918832, content=尊重科学,科学抗疫, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201221/137a6965d29349108c0e34d1034c142d/7d4214f027494937a9ccbccf0d523684.jpg, createdBy=84b02217108, createdName=孤舟蓑笠一老翁, createdTime=Sat Jan 23 12:22:07 CST 2021, time=2021-01-23, status=1, ipAttribution=)]
    2022-04-18 屋顶瞄爱赏月

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1212082, encodeId=53251212082d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Apr 18 08:09:07 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849168, encodeId=6f1118491685d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Aug 13 11:15:23 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919315, encodeId=925691931572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210123/de3e3cb777b342e0a1c1276de5bf1b9a/9325fbaec7b940728d61b380ff227dde.jpg, createdBy=46a42697416, createdName=ent_xunmeng1987, createdTime=Sat Jan 23 23:15:25 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029022, encodeId=cde4102902231, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Jan 23 14:15:23 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919205, encodeId=d6839192052e, content=<a href='/topic/show?id=e0d7546812c' target=_blank style='color:#2F92EE;'>#托珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=428, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54681, encryptionId=e0d7546812c, topicName=托珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 23 13:55:49 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919188, encodeId=382091918832, content=尊重科学,科学抗疫, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201221/137a6965d29349108c0e34d1034c142d/7d4214f027494937a9ccbccf0d523684.jpg, createdBy=84b02217108, createdName=孤舟蓑笠一老翁, createdTime=Sat Jan 23 12:22:07 CST 2021, time=2021-01-23, status=1, ipAttribution=)]
    2021-08-13 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1212082, encodeId=53251212082d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Apr 18 08:09:07 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849168, encodeId=6f1118491685d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Aug 13 11:15:23 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919315, encodeId=925691931572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210123/de3e3cb777b342e0a1c1276de5bf1b9a/9325fbaec7b940728d61b380ff227dde.jpg, createdBy=46a42697416, createdName=ent_xunmeng1987, createdTime=Sat Jan 23 23:15:25 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029022, encodeId=cde4102902231, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Jan 23 14:15:23 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919205, encodeId=d6839192052e, content=<a href='/topic/show?id=e0d7546812c' target=_blank style='color:#2F92EE;'>#托珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=428, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54681, encryptionId=e0d7546812c, topicName=托珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 23 13:55:49 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919188, encodeId=382091918832, content=尊重科学,科学抗疫, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201221/137a6965d29349108c0e34d1034c142d/7d4214f027494937a9ccbccf0d523684.jpg, createdBy=84b02217108, createdName=孤舟蓑笠一老翁, createdTime=Sat Jan 23 12:22:07 CST 2021, time=2021-01-23, status=1, ipAttribution=)]
    2021-01-23 ent_xunmeng1987

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1212082, encodeId=53251212082d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Apr 18 08:09:07 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849168, encodeId=6f1118491685d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Aug 13 11:15:23 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919315, encodeId=925691931572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210123/de3e3cb777b342e0a1c1276de5bf1b9a/9325fbaec7b940728d61b380ff227dde.jpg, createdBy=46a42697416, createdName=ent_xunmeng1987, createdTime=Sat Jan 23 23:15:25 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029022, encodeId=cde4102902231, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Jan 23 14:15:23 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919205, encodeId=d6839192052e, content=<a href='/topic/show?id=e0d7546812c' target=_blank style='color:#2F92EE;'>#托珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=428, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54681, encryptionId=e0d7546812c, topicName=托珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 23 13:55:49 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919188, encodeId=382091918832, content=尊重科学,科学抗疫, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201221/137a6965d29349108c0e34d1034c142d/7d4214f027494937a9ccbccf0d523684.jpg, createdBy=84b02217108, createdName=孤舟蓑笠一老翁, createdTime=Sat Jan 23 12:22:07 CST 2021, time=2021-01-23, status=1, ipAttribution=)]
    2021-01-23 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1212082, encodeId=53251212082d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Apr 18 08:09:07 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849168, encodeId=6f1118491685d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Aug 13 11:15:23 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919315, encodeId=925691931572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210123/de3e3cb777b342e0a1c1276de5bf1b9a/9325fbaec7b940728d61b380ff227dde.jpg, createdBy=46a42697416, createdName=ent_xunmeng1987, createdTime=Sat Jan 23 23:15:25 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029022, encodeId=cde4102902231, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Jan 23 14:15:23 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919205, encodeId=d6839192052e, content=<a href='/topic/show?id=e0d7546812c' target=_blank style='color:#2F92EE;'>#托珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=428, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54681, encryptionId=e0d7546812c, topicName=托珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 23 13:55:49 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919188, encodeId=382091918832, content=尊重科学,科学抗疫, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201221/137a6965d29349108c0e34d1034c142d/7d4214f027494937a9ccbccf0d523684.jpg, createdBy=84b02217108, createdName=孤舟蓑笠一老翁, createdTime=Sat Jan 23 12:22:07 CST 2021, time=2021-01-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1212082, encodeId=53251212082d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Mon Apr 18 08:09:07 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849168, encodeId=6f1118491685d, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Aug 13 11:15:23 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919315, encodeId=925691931572, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210123/de3e3cb777b342e0a1c1276de5bf1b9a/9325fbaec7b940728d61b380ff227dde.jpg, createdBy=46a42697416, createdName=ent_xunmeng1987, createdTime=Sat Jan 23 23:15:25 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029022, encodeId=cde4102902231, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Jan 23 14:15:23 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919205, encodeId=d6839192052e, content=<a href='/topic/show?id=e0d7546812c' target=_blank style='color:#2F92EE;'>#托珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=428, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54681, encryptionId=e0d7546812c, topicName=托珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 23 13:55:49 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919188, encodeId=382091918832, content=尊重科学,科学抗疫, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201221/137a6965d29349108c0e34d1034c142d/7d4214f027494937a9ccbccf0d523684.jpg, createdBy=84b02217108, createdName=孤舟蓑笠一老翁, createdTime=Sat Jan 23 12:22:07 CST 2021, time=2021-01-23, status=1, ipAttribution=)]
    2021-01-23 孤舟蓑笠一老翁

    尊重科学,科学抗疫

    0

相关资讯

J Transl Med:托珠单抗治疗COVID-19的有效性和安全性分析

托珠单抗可阻断白细胞介素-6(IL-6)的促炎活性,IL-6与肺炎的发生有关,而肺炎是COVID-19患者最常见的死亡原因。一项多中心、单臂、假设驱动的试验探究了托珠单抗治疗COVID-19的有效性和

NEJM:托珠单抗用于新冠肺炎住院患者的治疗

对于未进行机械通气的新冠肺炎住院患者,在标准护理基础上添加托珠单抗可降低患者机械通气或死亡风险,但对改善患者生存率无显著帮助

Lancet Neurology:托珠单抗与硫唑嘌呤治疗高度复发性视神经脊髓炎频谱障碍(TANGO)的安全性和有效性:一项开放性、多中心、随机、2期试验

视神经脊髓炎(NMOSD)是一种严重的中枢神经系统致残性炎症性自身免疫性疾病,常伴有水通道蛋白-4(AQP-4)的病理性体液免疫反应。这种疾病最常见的特征是反复复发的视神经炎和纵向广泛的横向脊髓炎。

托珠单抗中国获批用于治疗CAR-T疗法引起的细胞因子风暴

日前,罗氏托珠单抗注射液(商品名:雅美罗)获得国家药监局批准,用于成年和2岁及以上儿童患者由嵌合抗原受体(CAR)T细胞引起的重度或危及生命的细胞因子释放综合征(CRS)。

EClinicalMedicine:托珠单抗治疗会增加COVID-19重症患者死亡风险

自2020年3月以来,COVID-19疫情对西班牙卫生系统带来了挑战。一些可用疗法(抗疟药物、抗病毒药物、生物制剂)均是基于临床病例观察或基础科学数据。本研究目的是表征COVID-19重症患者的特点和

Lancet respirat med:托珠单抗治疗系统性硬化症的3期临床试验结果

托珠单抗(tocilizumab)是一种抗白介素6受体抗体,已有的2期试验提示其在系统性硬化症中具有一定疗效。本研究进一步开展了一项随机对照3期试验,以评估托珠单抗系统性硬化症的疗效和安全性。